Biomarker Data in Melanoma Presented at ASCO 2018 Are Largely Extensions of Previous Studies Rather Than New Discoveries

Sanjiv S. Agarwala, MD

Dr Sanjiv Agarwala argues that much of the biomarker data in melanoma presented at ASCO 2018 are around the value of PD-L1 testing; however, even PD-L1–negative melanoma patients seem to respond to anti–PD-1 therapy, although some studies suggest PD-L1–negative patients may be better candidates for combination immunotherapy.

Related Videos

January 16, 2019

Overcoming Challenges to Molecular Biomarker Testing

Drs. Geoffrey Oxnard and Lauren Ritterhouse discuss the challenges in biomarker testing—tissue stewardship and complexity of biomarker tests and results—and ways to overcome these challenges—improved communication among all members of the cancer care team and simplification of biomarker test results to focus on actionable biomarkers.

September 2, 2015

Overview of Ixazomib

Dixie-Lee Esseltine, MD provides a brief overview of the dosing schedule and indications of ixazomib. She also reviews the phase 3 clinical trials of ixazomib that are currently ongoing.